Macrophage expressed tartrate‐resistant acid phosphatase 5 promotes pulmonary fibrosis progression
Immunology · 2024
DOI: 10.1111/imm.13748 ↗Kurz gefasst
Fachartikel in der Zeitschrift Immunology, 2024. Verfasst von Jesper Bergwik und 9 weiteren Autor:innen. Beteiligte Einrichtung: Respiratory Medicine, Allergology & Palliative Medicine, Department of Clinical Sciences Lund, Lund University and Skåne University Hospital, Lund, S…. Hauptthemen laut MEDLINE: Lung, Idiopathic Pulmonary Fibrosis. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 48 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Stiftelsen Lars Hiertas Minne, Vetenskapsrådet, Cancerfonden.
Abstract (Originalsprache)
Idiopathic pulmonary fibrosis (IPF) is a progressive lung disorder involving scarring of pulmonary tissue and a subsequent decrease in respiratory capacity, ultimately resulting in death. Tartrate resistant acid phosphatase 5 (ACP5) plays a role in IPF but the exact mechanisms are yet to be elucidated. In this study, we have utilized various perturbations of the bleomycin mouse model of IPF including genetic knockout, RANKL inhibition, and macrophage adoptive transfer to further understand ACP5's role in pulmonary fibrosis. Genetic ablation of Acp5 decreased immune cell recruitment to the lungs and reduced the levels of hydroxyproline (reflecting extracellular matrix‐production) as well as histological damage. Additionally, gene expression profiling of murine lung tissue revealed downregulation of genes including Ccl13 , Mmp13 , and Il‐1α that encodes proteins specifically related to immune cell recruitment and macrophage/fibroblast interactions. Furthermore, antibody‐based neutralization of RANKL, an important inducer of Acp5 expression, reduced immune cell recruitment but did not decrease fibrotic lung development. Adoptive transfer of Acp5 −/− bone marrow‐derived monocyte (BMDM) macrophages 7 or 14 days after bleomycin administration resulted in reductions of cytokine production and decreased levels of lung damage, compared to adoptive transfer of WT control macrophages. Taken together, the data presented in this study suggest that macrophage derived ACP5 plays an important role in development of pulmonary fibrosis and could present a tractable target for therapeutic intervention in IPF.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Respiratory Medicine, Allergology & Palliative Medicine, Department of Clinical Sciences Lund, Lund University and Skåne University Hospital, Lund, Sweden.
- Lund Stem Cell Center, Lund University, Lund, Sweden.
- Wallenberg Center for Molecular Medicine, Lund University, Lund, Sweden.
- Cardiothoracic Surgery, Department of Clinical Sciences, Lund University, Skåne University Hospital, Lund, Sweden.
- Division of Pathology, Department of Laboratory Medicine, Karolinska Institutet, Stockholm, Sweden.
ORCID-Profile: Jesper Bergwik
Förderung
- Stiftelsen Lars Hiertas Minne
- Vetenskapsrådet
- Cancerfonden
- The Alfred Österlund Foundation
- Swedish Government Funds for Clinical Research
- Hjärt-Lungfonden
- Landshövding Per Westlings Minnesfond RMh
- Tore Nilssons Stiftelse
Zitieren
APA
Bergwik, J., Bhongir, R. K. V., Padra, M., Adler, A., Olm, F., Lång, P., Lindstedt, S., Andersson, G., Egesten, A., & Tanner, L. (2024). Macrophage expressed tartrate‐resistant acid phosphatase 5 promotes pulmonary fibrosis progression. Immunology. https://doi.org/10.1111/imm.13748
Vancouver
Bergwik J, Bhongir RKV, Padra M, Adler A, Olm F, Lång P, et al. Macrophage expressed tartrate‐resistant acid phosphatase 5 promotes pulmonary fibrosis progression. Immunology. 2024. doi:10.1111/imm.13748
BibTeX
@article{Bergwik2024,
author = {Bergwik, Jesper and Bhongir, Ravi Kiran Varma and Padra, Médea and Adler, Anna and Olm, Franziska and Lång, Pernilla and Lindstedt, Sandra and Andersson, Göran and Egesten, Arne and Tanner, Lloyd},
title = {Macrophage expressed tartrate‐resistant acid phosphatase 5 promotes pulmonary fibrosis progression},
journal = {Immunology},
year = {2024},
doi = {10.1111/imm.13748}
}
EUVIMED